Hematologic Malignancy

Dear Colleagues,

Hematologic malignancies have always represented a highly dynamic field for biologic and translational research, that rapidly impacts the clinical practice.
Recently, the ever more refined risk stratifications, based on molecular biomarkers and minimal residual disease assessment, and the advent of novel targeted agents, have increased the complexity of the clinical approach. Therefore, clinical decision making and patient management has become even more challenging, with particular impact on to allogeneic transplant indications.
The deeper understanding of the biologic characteristics of many hematologic malignancies and in particular of their genomic landscape, allowed the identification of specific therapeutic targets that have profoundly modified the treatment of our patients.
Among these new therapeutic modalities, we can cite in lymphoblastic leukemias and lymphomas the advent of innovative immunologic approaches, such as monoclonal antibodies, Bite, Darts, checkpoint inhibitors and CAR-T cell, while in acute myeloid leukemias the molecular-based therapies and the new cytotoxic formulations, as FLT3 inhibitors, gentuzumab/ozogamycin, CPX351.
In chronic myeloproliferative neoplasms, multiple myeloma and chronic lymphocytic leukemia, a continuous effort is ongoing to tailor the treatment on patients and disease characteristics, to optimize the use of the numerous biologic and targeted therapies
It is therefore a great pleasure to invite you to contribute to the current Special Issue. Its aim is to update biological and clinical aspects of hematologic malignancies, with research as well as review articles addressing the state of the art and the future perspectives of hematologic malignancies, focusing preferentially on innovative research in biology, diagnosis, prognosis and therapy.

Dr. Nicola Stefano Fracchiolla
Prof. Dr. Francesco Onida
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.